AIM:CIR

Stock Analysis Report

Executive Summary

Circassia Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of respiratory products.

Snowflake

Fundamentals

Imperfect balance sheet with limited growth.


Similar Companies

Share Price & News

How has Circassia Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

10.1%

AIM:CIR

-0.3%

GB Biotechs

1.6%

GB Market


1 Year Return

-76.0%

AIM:CIR

24.1%

GB Biotechs

0.3%

GB Market

CIR underperformed the Biotechs industry which returned 24% over the past year.

CIR underperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned 0.3% over the past year.


Share holder returns

CIRIndustryMarket
7 Day10.1%-0.3%1.6%
30 Day-2.2%3.3%5.7%
90 Day2.3%2.1%1.3%
1 Year-76.0%-76.0%25.0%24.1%5.1%0.3%
3 Year-81.1%-81.1%11.9%9.9%23.7%9.0%
5 Year-94.0%-94.0%54.6%50.9%29.9%2.5%

Price Volatility Vs. Market

How volatile is Circassia Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

1 year ago | Simply Wall St

March Top Growth Stocks To Buy

1 year ago | Simply Wall St

Best Growth Stocks To Buy Now

1 year ago | Simply Wall St

Best LSE Growth Stocks

Valuation

Is Circassia Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

0.51x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Circassia Pharmaceuticals to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Circassia Pharmaceuticals to establish if it is available at substantial discount.


Price Based on Earnings

Circassia Pharmaceuticals is loss making, we can't compare its value to the GB Biotechs industry average.

Circassia Pharmaceuticals is loss making, we can't compare the value of its earnings to the United Kingdom of Great Britain and Northern Ireland market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Circassia Pharmaceuticals, we can't assess if its growth is good value.


Price Based on Value of Assets

Circassia Pharmaceuticals is good value based on assets compared to the GB Biotechs industry average.


Next Steps

Future Growth

How is Circassia Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

69.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Circassia Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.

Circassia Pharmaceuticals is not considered high growth as it is expected to be loss making for the next 1-3 years.

Circassia Pharmaceuticals's revenue growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.

Unable to compare Circassia Pharmaceuticals's earnings growth to the United Kingdom of Great Britain and Northern Ireland market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Circassia Pharmaceuticals's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Circassia Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Circassia Pharmaceuticals performed over the past 5 years?

-18.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Circassia Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Circassia Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Circassia Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Circassia Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Circassia Pharmaceuticals has efficiently used its assets last year compared to the GB Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Circassia Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Circassia Pharmaceuticals's financial position?


Financial Position Analysis

Circassia Pharmaceuticals's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

Circassia Pharmaceuticals's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Circassia Pharmaceuticals has no debt.

Circassia Pharmaceuticals has no debt compared to 5 years ago when it was 6.2%.


Balance Sheet

Low level of unsold assets.

Circassia Pharmaceuticals has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Circassia Pharmaceuticals has less than a year of cash runway based on current free cash flow.

Circassia Pharmaceuticals has less than a year of cash runway if free cash flow continues to reduce at historical rates of -18.2% each year.


Next Steps

Dividend

What is Circassia Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Circassia Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Circassia Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Circassia Pharmaceuticals has not reported any payouts.

Unable to verify if Circassia Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Circassia Pharmaceuticals has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Circassia Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for United Kingdom of Great Britain and Northern Ireland.


Next Steps

Management

What is the CEO of Circassia Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

7.7yrs

Average management tenure


CEO

Steve Harris (52yo)

13.3yrs

Tenure

UK£669,000

Compensation

Mr. Steven Charles Andrew Harris, also known as Steve, co-founded Circassia Pharmaceuticals plc on March 19, 2006 and has been its Chief Executive Officer since March 19, 2006. Mr. Harris is a bioscience e ...


CEO Compensation Analysis

Steve's remuneration is higher than average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.

Steve's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

7.7yrs

Average Tenure

53yo

Average Age

The average tenure for the Circassia Pharmaceuticals management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

3.7yrs

Average Tenure

53.5yo

Average Age

The tenure for the Circassia Pharmaceuticals board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Steve Harris (52yo)

    Co-Founder

    • Tenure: 13.3yrs
    • Compensation: UK£669.00k
  • Rod Hafner (53yo)

    Senior Vice President of Research & Development

    • Tenure: 11.5yrs
    • Compensation: UK£464.00k
  • Julien Cotta (55yo)

    CFO, Company Secretary & Director

    • Tenure: 5.8yrs
    • Compensation: UK£434.00k
  • David Acheson

    Senior Vice President of US Commercial

    • Tenure: 2.7yrs
  • Jonathan Emms

    COO & Executive Director

    • Tenure: 0yrs
  • Nina Kataria

    Senior Vice President Global Human Resources

    • Tenure: 5.3yrs
  • Darren Mercer

    Senior Vice President of EU & RoW Commercial

    • Tenure: 0yrs

Board Members

  • Steve Harris (52yo)

    Co-Founder

    • Tenure: 13.3yrs
    • Compensation: UK£669.00k
  • Francesco Granata (68yo)

    Chairman

    • Tenure: 6yrs
    • Compensation: UK£151.00k
  • Julien Cotta (55yo)

    CFO, Company Secretary & Director

    • Tenure: 5.8yrs
    • Compensation: UK£434.00k
  • Jonathan Emms

    COO & Executive Director

    • Tenure: 0yrs
  • Le Jo

    Non-Executive Director

    • Tenure: 1.6yrs
    • Compensation: UK£55.00k
  • Sharon Curran (51yo)

    Non-Executive Director

    • Tenure: 1.6yrs
    • Compensation: UK£49.00k

Company Information

Circassia Pharmaceuticals plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Circassia Pharmaceuticals plc
  • Ticker: CIR
  • Exchange: AIM
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£67.434m
  • Shares outstanding: 374.63m
  • Website: https://www.circassia.com

Number of Employees


Location

  • Circassia Pharmaceuticals plc
  • Northbrook House
  • Robert Robinson Avenue
  • Oxford
  • Oxfordshire
  • OX4 4GA
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CIRAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPMar 2014
82CDB (Deutsche Boerse AG)YesOrdinary SharesDEEURMar 2014
CSSP.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDMar 2014

Biography

Circassia Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of respiratory products. It operates through NIOX and US AZ Collaboration segments. The c ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/14 21:38
End of Day Share Price2019/09/13 00:00
Earnings2018/12/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.